-
公开(公告)号：US07001942B2
公开(公告)日：2006-02-21
申请号：US10829443
申请日：2004-04-22
CPC分类号： C08J3/203 , C08K3/016 , C08K3/32 , Y10T428/31504
摘要： Articles and processes are provided whereby flame-retardant SAP particles are incorporated into synthetic resins, especially curable thermosettable resins. The SAP particles are most preferably hydrated with an aqueous flame-retardant solution. In this regard, the flame-retardant solution may consist essentially of water alone or a water solution containing one or more water soluble inorganic flame retardants. When SAP particles are hydrated with an aqueous inorganic flame retardant solution, the SAP particles may thereafter be dried to remove substantially the water component. In such a manner, the inorganic flame retardant will remain as a dried residue physically entrained within the SAP particles. As such, the SAP particles serve as a physical matrix in which the inorganic flame retardant is homogenously dispersed. The SAP particles may then be blended with a synthetic resin as is or alternatively may be ground into more finely divided particles which contain the dried residue of the aqueous inorganic flame retardant solution and then blended with a suitable synthetic resin.
摘要翻译： 提供了制品和方法，其中阻燃SAP颗粒被并入合成树脂，特别是可固化的可热固树脂中。 SAP颗粒最优选用含水阻燃溶液水合。 在这方面，阻燃溶液可以基本上由单独的水或含有一种或多种水溶性无机阻燃剂的水溶液组成。 当SAP颗粒与含水无机阻燃剂溶液水合时，此后可将SAP颗粒干燥以除去基本上水分。 以这种方式，无机阻燃剂将保留为物理夹带在SAP颗粒内的干燥残余物。 因此，SAP颗粒用作其中无机阻燃剂均匀分散的物理基体。 然后可以将SAP颗粒与合成树脂共混，或者可以研磨成更细的颗粒，其含有无机阻燃剂水溶液的干燥残余物，然后与合适的合成树脂混合。
-
2.发明授权Flame-retardant synthetic resin articles containing flame-retardant superabsorbent polymer (SAP) particles 失效含有阻燃超吸收聚合物（SAP）颗粒的阻燃合成树脂制品公开(公告)号：US07329461B2
公开(公告)日：2008-02-12
申请号：US11121942
申请日：2005-05-05
IPC分类号： C08K5/49
CPC分类号： C08J3/203 , C08K3/016 , C08K3/32 , Y10T428/31504
摘要： Flame-retardant synthetic resin articles and methods of making the same are provided whereby flame-retardant SAP particles are incorporated into synthetic resins, especially curable thermosettable resins. The SAP particles are most preferably hydrated with an aqueous flame-retardant solution. In this regard, the flame-retardant solution may consist essentially of water alone or a water solution containing one or more water soluble inorganic flame retardants. When SAP particles are hydrated with an aqueous inorganic flame retardant solution, the SAP particles may thereafter be dried to remove substantially the water component. In such a manner, the inorganic flame retardant will remain as a dried residue physically entrained within the SAP particles. As such, the SAP particles serve as a physical matrix in which the inorganic flame retardant is homogenously dispersed. The SAP particles may then be blended with a synthetic resin as is or alternatively may be ground into more finely divided particles which contain the dried residue of the aqueous inorganic flame retardant solution and then blended with a suitable synthetic resin.
摘要翻译： 提供阻燃合成树脂制品及其制备方法，其中阻燃SAP颗粒被引入合成树脂，特别是可固化的可热固树脂中。 SAP颗粒最优选用含水阻燃溶液水合。 在这方面，阻燃溶液可以基本上由单独的水或含有一种或多种水溶性无机阻燃剂的水溶液组成。 当SAP颗粒与含水无机阻燃剂溶液水合时，此后可将SAP颗粒干燥以除去基本上水分。 以这种方式，无机阻燃剂将保留为物理夹带在SAP颗粒内的干燥残余物。 因此，SAP颗粒用作其中无机阻燃剂均匀分散的物理基体。 然后可以将SAP颗粒与合成树脂共混，或者可以研磨成更细的颗粒，其含有无机阻燃剂水溶液的干燥残余物，然后与合适的合成树脂混合。
-
公开(公告)号：US08043609B2
公开(公告)日：2011-10-25
申请号：US11612751
申请日：2006-12-19
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
CPC分类号： A61K38/162 , A61K9/0051 , A61K38/17
摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
摘要翻译： 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成，眼部炎症或其任何组合的其它病症的组合物和方法。 某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。 其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分 变性或相关病症或脉络膜新生血管形成，眼部炎症或这些的任何组合。 某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。
-
公开(公告)号：US20110092446A1
公开(公告)日：2011-04-21
申请号：US12669957
申请日：2008-07-21
申请人： Cedric Francois , Pascal Deschatelets , Paul Olson
发明人： Cedric Francois , Pascal Deschatelets , Paul Olson
CPC分类号： A61K38/12 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156
摘要： The present invention features the use of a complement inhibitor, e.g., a compstatin analog for treating an individual who has suffered a severe injury. In some embodiments, the complement inhibitor may be administered within 24 hours following the injury and optionally also at later time points. The complement inhibitor may, for example, be administered prior to transporting the patient to a health care facility, during transport of the patient to a health care facility, or in the emergency department. Further provided are methods of selecting individuals for such therapy. Further provided are methods of identifying individuals at increased risk of poor outcome following trauma. In certain embodiments the methods comprise determining whether the genotype of the patient includes an allele of a polymorphism in or near a complement-related gene, wherein said allele is associated with risk of poor outcome following trauma.
摘要翻译： 本发明的特征在于补体抑制剂例如化合物类似物用于治疗遭受严重损伤的个体的用途。 在一些实施方案中，补体抑制剂可以在损伤后24小时内和任选地也在稍后的时间点施用。 例如，补体抑制剂可以在将患者运送到保健设施之前，在将患者运送到保健设施或急诊部门期间进行给药。 还提供了选择这种治疗的个体的方法。 进一步提供的是识别创伤后不良结局风险增加的个体的方法。 在某些实施方案中，所述方法包括确定患者的基因型是否包括在补体相关基因中或其附近的多态性的等位基因，其中所述等位基因与创伤后的结果不良的风险相关。
-
5.发明申请CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF 审中-公开细胞反应性，长期作用或靶向的同型异基体类似物及其用途公开(公告)号：US20140323407A1
公开(公告)日：2014-10-30
申请号：US14116591
申请日：2012-05-11
CPC分类号： C07K7/64 , A61K38/00 , A61K47/60 , A61K47/643 , C07K7/08 , C07K14/472
摘要： In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.
摘要翻译： 在一些方面，本发明提供了细胞反应性抑制剂类似物和包含细胞反应性compstatin类似物的组合物。 在一些方面，本发明还提供了使用细胞反应性化合物抑制物类似物的方法，例如抑制补体介导的对细胞，组织或器官的损伤。 在一些方面，本发明提供了长效化合物抑制素类似物和包含长效化合物抑制素类似物的组合物。 在一些方面，本发明进一步提供使用长效抑制剂类似物的方法，例如抑制补体介导的对细胞，组织或器官的损伤。 在一些方面，本发明提供靶向化合物抑制素类似物和包含目标化合物抑制物类似物的组合物。 在一些方面，本发明还提供了使用靶标化合物抑制素类似物的方法，例如抑制补体介导的对细胞，组织或器官的损伤。
-
6.发明申请公开(公告)号：US20130324482A1
公开(公告)日：2013-12-05
申请号：US13809274
申请日：2011-07-08
摘要： In some aspects, the present invention provides methods treating a subject in need of treatment for chronic rhinosinusitis or nasal polyposis, the methods comprising administering a complement inhibitor such as a compstatin analog to the subject. In some embodiments, the complement inhibitor is administered intranasally, e.g., in a nasal spray.
摘要翻译： 在一些方面，本发明提供了治疗需要治疗慢性鼻鼻窦炎或鼻息肉病的受试者的方法，所述方法包括向受试者施用补体抑制剂，例如化合物类似物。 在一些实施方案中，补体抑制剂是鼻内施用的，例如鼻喷雾剂。
-
7.发明授权公开(公告)号：US08198020B2
公开(公告)日：2012-06-12
申请号：US10923940
申请日：2004-08-23
IPC分类号： C12Q1/70 , C12Q1/00 , G01N33/53 , G01N33/567 , G01N33/574
CPC分类号： B82Y5/00 , A61K47/544 , A61K47/62 , A61K47/6911 , A61K47/6913
摘要： The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.
摘要翻译： 本发明提供了一种用于通过用靶向细胞或非细胞分子实体进行吞噬作用（吞噬标记）的标记来标记这样的细胞或非细胞分子实体来增强不需要的细胞或非细胞分子实体的清除或破坏的系统。 靶细胞可以是例如内皮细胞，肿瘤细胞，白细胞或病毒感染的细胞。 在本发明的某些实施方案中，标记通过施用包含与噬菌体标记物连接的抗体或配体的组合物来实现，其中所述抗体或配体结合存在于靶细胞的细胞表面上或细胞表面的细胞类型特异性标志物。 在本发明的优选实施方案中，吞噬标记物包含磷脂酰丝氨酸或衍生自磷脂酰丝氨酸，血小板反应素-1，膜联蛋白I或其任何衍生物的基团。
-
公开(公告)号：US20080075755A1
公开(公告)日：2008-03-27
申请号：US11612751
申请日：2006-12-19
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
CPC分类号： A61K38/162 , A61K9/0051 , A61K38/17
摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
摘要翻译： 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成，眼部炎症或其任何组合的其它病症的组合物和方法。 某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。 其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分 变性或相关病症或脉络膜新生血管形成，眼部炎症或这些的任何组合。 某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。
-
公开(公告)号：US20070295395A1
公开(公告)日：2007-12-27
申请号：US10594073
申请日：2005-03-25
IPC分类号： H01L31/04 , H01L31/0256 , H01L51/00
CPC分类号： H01L51/4253 , B82Y10/00 , B82Y30/00 , B82Y40/00 , C01B32/15 , C01B32/152 , H01L51/0036 , H01L51/0037 , H01L51/0046 , H01L51/0077 , H01L51/0089 , H01L51/424 , Y02E10/549
摘要： An exemplary photovoltaic device for conversion of an incident wavelength of electromagnetic radiation to electricity has an absorber of incident wavelength of electromagnetic radiation, a trimetasphere in electron transferring contact with the absorber, an anode in electrical contact with the trimetasphere, and a cathode in electrical contact with the absorber. The absorber and trimetasphere can be arranged as a heterojunction or a blended junction. An exemplary electrical circuit has an absorber of incident electromagnetic radiation, a trimetasphere-containing material in electron transferring contact with the absorber, an anode, a cathode and a current path from the anode to the cathode. An exemplary method of converting incident electromagnetic radiation to an electrical signal using a trimetasphere-containing material is also disclosed.
摘要翻译： 用于将电磁辐射的入射波长转换为电的示例性光伏器件具有电磁辐射的入射波长的吸收体，与吸收体的电子转移接触的三角肌，与三角肌电接触的阳极和电接触的阴极 与吸收器。 吸收体和三角突耳可以排列成异质结或混合结。 示例性电路具有入射电磁辐射的吸收体，与吸收体电子转移接触的含三聚甲醛的材料，阳极，阴极和从阳极到阴极的电流路径。 还公开了一种用入射电磁辐射将电子信号转换为电信号的示例性方法。
-
公开(公告)号：US20070142202A1
公开(公告)日：2007-06-21
申请号：US11657930
申请日：2007-01-24
CPC分类号： B81C99/008 , B28B7/342 , B28B13/021 , B81C99/0085 , B81C2201/034 , B82Y10/00 , B82Y30/00 , C04B35/571 , C04B35/589 , C04B35/622 , Y10T428/26
摘要： The invention provides ceramic molded solid articles and methods for making these articles on the micron scale. Articles are molded from ceramic precursors, optionally using molds including at least one portion that is elastomeric.
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.039 秒)
